Chronic Disease
Featured Topics
Lead story
Other featured articles
-
Newly Approved Cancer Drugs Are Pricey, But Also Show Improved Longer-Term Survival Gains, According to New Study
Do the clinical gains offered by these drugs in treating specific cancer indications justify the price increases? Schaeffer Center researchers Alice Chen and Dana Goldman explore how we might measure the value of these drugs.
Posted in -
Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?
This study provides the first evidence to our knowledge that near-universal access to Medicare at age 65 is associated with improvements in population-level cancer mortality, and provides new evidence on the differences in the impact of health insurance by gender.
Posted in -
Who Would Have Believed it? Markets Can Reduce the ‘True’ Price of Cancer Drugs
When it comes to cancer, however, it is the price of health — not the price of drugs — that matters. As we think about ways to wring value out of the health care system, we acknowledge that CMS reforms and markets seem to be working in therapeutic areas with rapid innovation.
Posted in -
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Posted in
About this section
Chronic diseases are among the most preventable and costliest conditions, consuming the overwhelming majority of Medicare resources. The Schaeffer Center assembles leading minds from across disciplines to address this challenge, striving to simplify labyrinthine systems of care and promote healthier outcomes.
Our Experts On Chronic Disease
Our Work In Chronic Disease
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Using the Drug Pricing Netflix Model to Help States Tackle the Hep C Crisis
Researcher Neeraj Sood has explored innovative payment models as a strategy for government entities to be able to pay for lifesaving cures that could eradicate diseases like hepatitis C. Louisiana, with some input from Sood, has just implemented a modified version of a subscription model to pay for Hep C treatments.
-
Contribution Of Care Source To Cancer Treatment Cost Variation In The US Military Health System
Seth Seabury and colleagues examined how care received from military treatment facilities or purchased care in civilian facilities contributed to cancer treatment costs for patients.
-
Don’t Let the New Kidney Health Initiative Fade from View
As a kidney doctor and health policy researcher, I am surprised that President Donald Trump’s initiative to remake kidney treatment has not gotten more attention. We need to keep paying attention because so much is at stake.
Categorized in -
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
-
Louisiana’s Prescription Drug Experiment: A Model for the Nation?
On July 22, the USC-Brookings Schaeffer Initiative for Health Policy will hosted a conference on Louisiana’s subscription model to expand access to Hepatitis C treatment for the state’s incarcerated and Medicaid patients with the infection.
Categorized in